News
ATXI
--
0.00%
--
How Much Of Avenue Therapeutics, Inc. (NASDAQ:ATXI) Do Institutions Own?
Simply Wall St. · 01/12 04:32
Is Avenue Therapeutics (ATXI) Stock a Buy For 2021?
Clark Street Value sold 2/3rds of its position in Avenue Therapeutics Inc. (NASDAQ:ATXI) stock. Clark Street Value is an individual investor that is focused on finding value and special situation investments. Avenue Therapeutics Inc. (NASDAQ:ATXI) is a pha...
Insider Monkey · 01/06 14:23
Virgin Galactic Holdings, Wunong Net Technology leads premarket losers' pack
Mesoblast (MESO) -31% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19.Wunong Net Technology Company (WNW) -18%.Applied DNA Sciences (APDN) -16% on Q4 earnings release.Takung Art (TKAT) -14%.Virgin Galactic
Seekingalpha · 12/18/2020 13:18
Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that a publication titled "Real-World Data on Nonmedical Use of Tramadol from Patients Evaluated for S...
GlobeNewswire · 12/18/2020 13:00
Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that a publication titled "Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis...
GlobeNewswire · 12/18/2020 13:00
Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis
GlobeNewswire · 12/18/2020 13:00
Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that a publication titled “Real-World Data on Nonmedical U...
GlobeNewswire · 12/18/2020 13:00
MARA, NXTD, ZYNE and SCYX among midday movers
Gainers: MingZhu Logistics (YGMZ) +237%.Nxt-ID (NXTD) +99%.PainReform (PRFX) +39%.Takung Art (TKAT) +39%.Avenue Therapeutics (ATXI) +31%.Eloxx Pharmaceuticals (ELOX) +30%.Jupiter Wellness (JUPW) +29%.Vivos Therapeutics (VVOS) +25%.Cogent Biosciences (COGT) +24%.Marathon Patent (MARA) +24%.Losers: Triterras (TRIT) -36%.BioCardia (BCDA) -28%.CooTek (CTK) -23%.MediaCo
Seekingalpha · 12/17/2020 17:41
Avenue Therapeutics issues regulatory update for IV tramadol
Avenue Therapeutics (ATXI) provides a regulatory update following November 2020 Type A meeting with the FDA relating to a path forward for IV tramadol. The meeting was requested to address
Seekingalpha · 12/17/2020 13:08
Avenue Therapeutics Provides Regulatory Update for IV Tramadol
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today provided a regulatory update following receipt of the official meeting minutes from a November 2020 Type A meeti...
GlobeNewswire · 12/17/2020 12:00
Read This Before Selling Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares
Simply Wall St. · 11/13/2020 10:28
Read This Before Selling Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Simply Wall St. · 11/13/2020 10:28
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 10/29/2020 11:30
The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 26)
Benzinga · 10/27/2020 12:24
The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22)
Benzinga · 10/23/2020 11:26
The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 21)
Benzinga · 10/22/2020 11:52
The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20)
Benzinga · 10/21/2020 12:04
The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference
Biopharma stocks, which started the week on a firm footing, lost momentum mid-way through amid market-wide sell-off triggered by waning stimulus hopes.
Benzinga · 10/18/2020 16:50
Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates
Zacks · 10/14/2020 15:10
Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates
Regeneron (REGN) and Gilead (GILD) continue to be in the spotlight on coronavirus-related updates.
Zacks · 10/14/2020 14:10
Webull provides a variety of real-time ATXI stock news. You can receive the latest news about Avenue through multiple platforms. This information may help you make smarter investment decisions.
About ATXI
Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing its product principally for use in the acute/intensive care hospital setting. The Company’s product candidate is intravenous (IV) Tramadol, for the treatment of moderate to moderately severe post-operative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Its Oral tramadol is marketed in the United States for moderate to moderately severe pain in adults. Its Parenteral tramadol formulations include IV, intramuscular (IM), and subcutaneous (SC) formulations. Tramadol is marketed in the United States under the trade name Ultram immediate release tablet. Ultracet is a combination product containing tramadol and acetaminophen, is also marketed in the United States.
More